Sanofi-Aventis SA is likely to be the sole buyer for Genzyme Corp. and end up paying $74 to $77 a share, or $19.7-20.5 billion, for the rare diseases specialist, according to Citigroup analysts.
*For more on this story, read the full Reuters article.
